4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Holdings Trimmed by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund lessened its position in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 35.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 459,000 shares of the company’s stock after selling 247,000 shares during the period. Healthcare of Ontario Pension Plan Trust Fund owned about 0.88% of 4D Molecular Therapeutics worth $4,962,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in 4D Molecular Therapeutics by 25.3% in the first quarter. Vanguard Group Inc. now owns 2,339,943 shares of the company’s stock worth $74,551,000 after purchasing an additional 473,094 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of 4D Molecular Therapeutics by 6.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,952 shares of the company’s stock valued at $764,000 after buying an additional 1,356 shares during the period. California State Teachers Retirement System grew its position in shares of 4D Molecular Therapeutics by 12.6% during the 1st quarter. California State Teachers Retirement System now owns 28,490 shares of the company’s stock valued at $908,000 after buying an additional 3,197 shares during the last quarter. Assenagon Asset Management S.A. raised its stake in 4D Molecular Therapeutics by 6.0% during the second quarter. Assenagon Asset Management S.A. now owns 456,267 shares of the company’s stock worth $9,577,000 after acquiring an additional 25,711 shares during the period. Finally, Nisa Investment Advisors LLC lifted its holdings in 4D Molecular Therapeutics by 5,735.7% in the second quarter. Nisa Investment Advisors LLC now owns 96,698 shares of the company’s stock worth $2,030,000 after acquiring an additional 95,041 shares during the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Stock Down 0.4 %

FDMT stock opened at $7.84 on Friday. The company has a 50-day simple moving average of $8.83 and a 200 day simple moving average of $15.89. The company has a market capitalization of $362.44 million, a P/E ratio of -2.75 and a beta of 2.82. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $7.32 and a fifty-two week high of $36.25.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. HC Wainwright reaffirmed a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. Royal Bank of Canada lowered their price objective on 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating for the company in a research note on Thursday, November 14th. Morgan Stanley initiated coverage on 4D Molecular Therapeutics in a research note on Thursday, November 21st. They issued an “underweight” rating and a $8.00 target price on the stock. Cantor Fitzgerald lowered shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, September 23rd. Finally, Leerink Partners reiterated an “outperform” rating and issued a $36.00 price objective (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Thursday, September 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $42.13.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.